RECOMBINANT THERAPEUTICS APPROVED FOR MARKETING IN INDIA

S. No.

Molecules

Therapeutic indications

1.

Human insulin

Diabetes

2.

Erythropoietin

Anemia

3.

Hepatitis B vaccine

(recombinant surface antigen based)

Hepatitis B

4.

Human growth hormone

Deficiency of growth hormone in children

5.

Interleukin 2

Renal cell carcinoma

6.

Interleukin 11

Thrombocytopenia

7.

Granulocyte Colony Stimulating Factor (GCSF)

Chemotherapy induced neutropenia

8.

Granulocyte Macrophage Colony Stimulating Factor (GMCSF)

Chemotherapy induced neutropenia

9.

Interferon-2a

Chronic myeloid leukemia

10.

Interferon-2b

Chronic myeloid leukemia, Hepatitis B and Hepatitis C

11.

Interferon-g

Chronic granulomatous disease and severe malignant osteopetrosis

12.

Streptokinase

Acute myocardial infarction

13.

Tissue Plasminogen Activator

Acute myocardial infarction

14.

Blood factor VIII

Haemophilia type A

15.

Follicle stimulating hormone

Reproductive disorders

16.

Teriparatide (Forteo)

Osteoporosis

17.

Drotrecogin (Xigris) alpha.

Severe sepsis

18.

Platelet Derived Growth Factor (PDGF)

Bone marrow induction and osteoblasts proliferation

19.

Epidermal Growth factor (EGF)

Mitogenesis and organ morphogenesis

20.

Eptacogalpha (r-F VIIa) r-coagulation factor

Haemorrhages, congenital or acquired hemophilia